# Actinium Pharmaceuticals, Inc.: financial statements, quarterly

ATNM · NYSE · CIK 1388320 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/atnm.md) · [Financials](/companies/atnm/financials.md) · [Filings](/companies/atnm/filings.md) · [Insiders](/companies/atnm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/atnm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001213900-25-110979.md) | [0.0 d](/filings/0001213900-26-036504.md) | not reported | [35.0](/filings/0001213900-26-086769.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [11.6](/filings/0001213900-24-098534.md) | [8.1 d](/filings/0001213900-25-026371.md) | [6.6](/filings/0001213900-25-041614.md) | [8.8](/filings/0001213900-25-073743.md) | [9.8](/filings/0001213900-25-110979.md) | [4.8 d](/filings/0001213900-26-036504.md) | [7.7](/filings/0001213900-26-053980.md) | [4.9](/filings/0001213900-26-086769.md) | [4.2](/filings/0001213900-25-110979.md) | [4.3 d](/filings/0001213900-26-036504.md) | [4.2](/filings/0001213900-26-053980.md) | [5.4](/filings/0001213900-26-086769.md) |
| Operating income | $m | [(14.4)](/filings/0001213900-24-098534.md) | [(10.3) d](/filings/0001213900-25-026371.md) | [(9.6)](/filings/0001213900-25-041614.md) | [(12.4)](/filings/0001213900-25-073743.md) | [(12.6)](/filings/0001213900-25-110979.md) | [(7.5) d](/filings/0001213900-26-036504.md) | [(16.6)](/filings/0001213900-26-053980.md) | [(7.5)](/filings/0001213900-26-086769.md) | [(5.7)](/filings/0001213900-25-110979.md) | [(6.4) d](/filings/0001213900-26-036504.md) | [(5.9)](/filings/0001213900-26-053980.md) | [27.6](/filings/0001213900-26-086769.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(13.3)](/filings/0001213900-24-098534.md) | [(9.3) d](/filings/0001213900-25-026371.md) | [(8.7)](/filings/0001213900-25-110979.md) | [(11.4)](/filings/0001213900-25-110979.md) | [(11.6)](/filings/0001213900-25-110979.md) | [(6.7) d](/filings/0001213900-26-036504.md) | [(15.9)](/filings/0001213900-26-086769.md) | [(6.9)](/filings/0001213900-26-086769.md) | [(5.1)](/filings/0001213900-25-110979.md) | [(5.9) d](/filings/0001213900-26-036504.md) | [(5.5)](/filings/0001213900-26-086769.md) | [27.9](/filings/0001213900-26-086769.md) |
| Diluted EPS | $ per share | [(0.49)](/filings/0001213900-24-098534.md) | not reported | [(0.31)](/filings/0001213900-25-041614.md) | [(0.38)](/filings/0001213900-25-073743.md) | [(0.37)](/filings/0001213900-25-110979.md) | not reported | [(0.51)](/filings/0001213900-26-053980.md) | [(0.22)](/filings/0001213900-26-086769.md) | [(0.16)](/filings/0001213900-25-110979.md) | not reported | [(0.18)](/filings/0001213900-26-053980.md) | [0.89](/filings/0001213900-26-086769.md) |
| Basic EPS | $ per share | [(0.49)](/filings/0001213900-24-098534.md) | not reported | [(0.31)](/filings/0001213900-25-041614.md) | [(0.38)](/filings/0001213900-25-073743.md) | [(0.37)](/filings/0001213900-25-110979.md) | not reported | [(0.51)](/filings/0001213900-26-053980.md) | [(0.22)](/filings/0001213900-26-086769.md) | [(0.16)](/filings/0001213900-25-110979.md) | not reported | [(0.18)](/filings/0001213900-26-053980.md) | [0.89](/filings/0001213900-26-086769.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [83.0](/filings/0001213900-23-082459.md) | [76.7](/filings/0001213900-25-026371.md) | [84.1](/filings/0001213900-24-036699.md) | [86.0](/filings/0001213900-24-065239.md) | [78.7](/filings/0001213900-24-098534.md) | [72.9](/filings/0001213900-26-036504.md) | [65.3](/filings/0001213900-25-041614.md) | [59.9](/filings/0001213900-25-073743.md) | [53.4](/filings/0001213900-25-110979.md) | [48.0](/filings/0001213900-26-086769.md) | [42.1](/filings/0001213900-26-053980.md) | [36.5](/filings/0001213900-26-086769.md) |
| Current assets | $m | [85.6](/filings/0001213900-23-082459.md) | [78.3](/filings/0001213900-25-026371.md) | [85.4](/filings/0001213900-24-036699.md) | [87.1](/filings/0001213900-24-065239.md) | [79.5](/filings/0001213900-24-098534.md) | [74.5](/filings/0001213900-26-036504.md) | [66.5](/filings/0001213900-25-041614.md) | [61.0](/filings/0001213900-25-073743.md) | [54.4](/filings/0001213900-25-110979.md) | [49.4](/filings/0001213900-26-086769.md) | [43.3](/filings/0001213900-26-053980.md) | [37.7](/filings/0001213900-26-086769.md) |
| Total assets | $m | [88.9](/filings/0001213900-23-082459.md) | [81.4](/filings/0001213900-25-026371.md) | [88.4](/filings/0001213900-24-036699.md) | [89.9](/filings/0001213900-24-065239.md) | [82.1](/filings/0001213900-24-098534.md) | [76.9](/filings/0001213900-26-036504.md) | [68.6](/filings/0001213900-25-041614.md) | [63.0](/filings/0001213900-25-073743.md) | [56.2](/filings/0001213900-25-110979.md) | [51.8](/filings/0001213900-26-086769.md) | [45.4](/filings/0001213900-26-053980.md) | [40.2](/filings/0001213900-26-086769.md) |
| Current liabilities | $m | [8.7](/filings/0001213900-23-082459.md) | [8.5](/filings/0001213900-25-026371.md) | [8.1](/filings/0001213900-24-036699.md) | [9.7](/filings/0001213900-24-065239.md) | [7.8](/filings/0001213900-24-098534.md) | [8.1](/filings/0001213900-26-036504.md) | [7.1](/filings/0001213900-25-041614.md) | [8.3](/filings/0001213900-25-073743.md) | [6.8](/filings/0001213900-25-110979.md) | [8.0](/filings/0001213900-26-086769.md) | [7.3](/filings/0001213900-26-053980.md) | [9.3](/filings/0001213900-26-086769.md) |
| Total liabilities | $m | [45.4](/filings/0001213900-23-082459.md) | [45.1](/filings/0001213900-25-026371.md) | [44.5](/filings/0001213900-24-036699.md) | [46.0](/filings/0001213900-24-065239.md) | [43.9](/filings/0001213900-24-098534.md) | [44.1](/filings/0001213900-26-036504.md) | [43.0](/filings/0001213900-25-041614.md) | [44.0](/filings/0001213900-25-073743.md) | [42.4](/filings/0001213900-25-110979.md) | [43.9](/filings/0001213900-26-086769.md) | [43.1](/filings/0001213900-26-053980.md) | [9.9](/filings/0001213900-26-086769.md) |
| Shareholders' equity | $m | [43.6](/filings/0001213900-24-098534.md) | [36.4](/filings/0001213900-26-036504.md) | [43.9](/filings/0001213900-25-110979.md) | [43.8](/filings/0001213900-25-110979.md) | [38.2](/filings/0001213900-25-110979.md) | [32.8](/filings/0001213900-26-086769.md) | [25.7](/filings/0001213900-26-086769.md) | [19.0](/filings/0001213900-26-086769.md) | [13.8](/filings/0001213900-25-110979.md) | [7.8](/filings/0001213900-26-086769.md) | [2.3](/filings/0001213900-26-086769.md) | [30.3](/filings/0001213900-26-086769.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.1) d](/filings/0001213900-24-098534.md) | [(7.5) d](/filings/0001213900-25-026371.md) | [(7.4)](/filings/0001213900-25-041614.md) | [(8.0) d](/filings/0001213900-25-073743.md) | [(12.0) d](/filings/0001213900-25-110979.md) | [(5.8) d](/filings/0001213900-26-036504.md) | [(7.6)](/filings/0001213900-26-053980.md) | [(5.4) d](/filings/0001213900-26-086769.md) | [(6.3) d](/filings/0001213900-25-110979.md) | [(5.3) d](/filings/0001213900-26-036504.md) | [(5.9)](/filings/0001213900-26-053980.md) | [(5.2) d](/filings/0001213900-26-086769.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001213900-24-098534.md) | [0.0 d](/filings/0001213900-25-026371.md) | [0.0](/filings/0001213900-25-041614.md) | [0.0 d](/filings/0001213900-25-073743.md) | [0.0 d](/filings/0001213900-25-110979.md) | [0.0 d](/filings/0001213900-26-036504.md) | not reported | not reported | not reported | not reported | [0.0](/filings/0001213900-26-053980.md) | [0.5 d](/filings/0001213900-26-086769.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [25.2](/filings/0001213900-23-082459.md) | [25.7](/filings/0001213900-24-036699.md) | [26.2](/filings/0001213900-24-065239.md) | [27.1](/filings/0001213900-24-098534.md) | [27.9](/filings/0001213900-25-041614.md) | [30.1](/filings/0001213900-25-073743.md) | [31.1](/filings/0001213900-25-110979.md) | [31.2](/filings/0001213900-26-053980.md) | [31.2](/filings/0001213900-26-086769.md) | [31.2](/filings/0001213900-25-110979.md) | [31.2](/filings/0001213900-26-053980.md) | [31.4](/filings/0001213900-26-086769.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 31,441,436 at 2026-08-06, from the cover of the [10-Q filed 2026-08-07](/filings/0001213900-26-086769.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.